1 Infectious Vaccines Market Overview
1.1 Product Overview and Scope of Infectious Vaccines
1.2 Infectious Vaccines Segment by Type
1.2.1 Global Infectious Vaccines Sales Growth Rate Comparison by Type (2023-2030)
1.2.2 Preventive Vaccine
1.2.3 Therapeutic Vaccine
1.3 Infectious Vaccines Segment by Application
1.3.1 Global Infectious Vaccines Sales Comparison by Application: (2023-2030)
1.3.2 Adults
1.3.3 Pediatrics
1.4 Global Infectious Vaccines Market Size Estimates and Forecasts
1.4.1 Global Infectious Vaccines Revenue 2018-2030
1.4.2 Global Infectious Vaccines Sales 2018-2030
1.4.3 Infectious Vaccines Market Size by Region: 2018 Versus 2022 Versus 2030
2 Infectious Vaccines Market Competition by Manufacturers
2.1 Global Infectious Vaccines Sales Market Share by Manufacturers (2018-2023)
2.2 Global Infectious Vaccines Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Infectious Vaccines Average Price by Manufacturers (2018-2023)
2.4 Manufacturers Infectious Vaccines Manufacturing Sites, Area Served, Product Type
2.5 Infectious Vaccines Market Competitive Situation and Trends
2.5.1 Infectious Vaccines Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Infectious Vaccines Players Market Share by Revenue
2.5.3 Global Infectious Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Infectious Vaccines Retrospective Market Scenario by Region
3.1 Global Infectious Vaccines Retrospective Market Scenario in Sales by Region: 2018-2023
3.2 Global Infectious Vaccines Retrospective Market Scenario in Revenue by Region: 2018-2023
3.3 North America Infectious Vaccines Market Facts & Figures by Country
3.3.1 North America Infectious Vaccines Sales by Country
3.3.2 North America Infectious Vaccines Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Infectious Vaccines Market Facts & Figures by Country
3.4.1 Europe Infectious Vaccines Sales by Country
3.4.2 Europe Infectious Vaccines Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Infectious Vaccines Market Facts & Figures by Region
3.5.1 Asia Pacific Infectious Vaccines Sales by Region
3.5.2 Asia Pacific Infectious Vaccines Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Infectious Vaccines Market Facts & Figures by Country
3.6.1 Latin America Infectious Vaccines Sales by Country
3.6.2 Latin America Infectious Vaccines Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Infectious Vaccines Market Facts & Figures by Country
3.7.1 Middle East and Africa Infectious Vaccines Sales by Country
3.7.2 Middle East and Africa Infectious Vaccines Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Infectious Vaccines Historic Market Analysis by Type
4.1 Global Infectious Vaccines Sales Market Share by Type (2018-2023)
4.2 Global Infectious Vaccines Revenue Market Share by Type (2018-2023)
4.3 Global Infectious Vaccines Price by Type (2018-2023)
5 Global Infectious Vaccines Historic Market Analysis by Application
5.1 Global Infectious Vaccines Sales Market Share by Application (2018-2023)
5.2 Global Infectious Vaccines Revenue Market Share by Application (2018-2023)
5.3 Global Infectious Vaccines Price by Application (2018-2023)
6 Key Companies Profiled
6.1 CSL Limited (Australia)
6.1.1 CSL Limited (Australia) Corporation Information
6.1.2 CSL Limited (Australia) Description and Business Overview
6.1.3 CSL Limited (Australia) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.1.4 CSL Limited (Australia) Infectious Vaccines Product Portfolio
6.1.5 CSL Limited (Australia) Recent Developments/Updates
6.2 Bavarian Nordic (Denmark)
6.2.1 Bavarian Nordic (Denmark) Corporation Information
6.2.2 Bavarian Nordic (Denmark) Description and Business Overview
6.2.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio
6.2.5 Bavarian Nordic (Denmark) Recent Developments/Updates
6.3 GlaxoSmithKline plc. (U.K.)
6.3.1 GlaxoSmithKline plc. (U.K.) Corporation Information
6.3.2 GlaxoSmithKline plc. (U.K.) Description and Business Overview
6.3.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.3.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio
6.3.5 GlaxoSmithKline plc. (U.K.) Recent Developments/Updates
6.4 Emergent Bio Solutions Inc. (U.S.)
6.4.1 Emergent Bio Solutions Inc. (U.S.) Corporation Information
6.4.2 Emergent Bio Solutions Inc. (U.S.) Description and Business Overview
6.4.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio
6.4.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments/Updates
6.5 MedImmune LLC (U.S.)
6.5.1 MedImmune LLC (U.S.) Corporation Information
6.5.2 MedImmune LLC (U.S.) Description and Business Overview
6.5.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.5.4 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio
6.5.5 MedImmune LLC (U.S.) Recent Developments/Updates
6.6 Johnson and Johnson (U.S.)
6.6.1 Johnson and Johnson (U.S.) Corporation Information
6.6.2 Johnson and Johnson (U.S.) Description and Business Overview
6.6.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio
6.6.5 Johnson and Johnson (U.S.) Recent Developments/Updates
6.7 Novartis AG (Switzerland)
6.6.1 Novartis AG (Switzerland) Corporation Information
6.6.2 Novartis AG (Switzerland) Description and Business Overview
6.6.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis AG (Switzerland) Infectious Vaccines Product Portfolio
6.7.5 Novartis AG (Switzerland) Recent Developments/Updates
6.8 Merck and Company (U.S.)
6.8.1 Merck and Company (U.S.) Corporation Information
6.8.2 Merck and Company (U.S.) Description and Business Overview
6.8.3 Merck and Company (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Merck and Company (U.S.) Infectious Vaccines Product Portfolio
6.8.5 Merck and Company (U.S.) Recent Developments/Updates
6.9 Sanofi Pasteur (France)
6.9.1 Sanofi Pasteur (France) Corporation Information
6.9.2 Sanofi Pasteur (France) Description and Business Overview
6.9.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Sanofi Pasteur (France) Infectious Vaccines Product Portfolio
6.9.5 Sanofi Pasteur (France) Recent Developments/Updates
6.10 Pfizer Inc. (U.S.)
6.10.1 Pfizer Inc. (U.S.) Corporation Information
6.10.2 Pfizer Inc. (U.S.) Description and Business Overview
6.10.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio
6.10.5 Pfizer Inc. (U.S.) Recent Developments/Updates
7 Infectious Vaccines Manufacturing Cost Analysis
7.1 Infectious Vaccines Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Infectious Vaccines
7.4 Infectious Vaccines Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Infectious Vaccines Distributors List
8.3 Infectious Vaccines Customers
9 Infectious Vaccines Market Dynamics
9.1 Infectious Vaccines Industry Trends
9.2 Infectious Vaccines Market Drivers
9.3 Infectious Vaccines Market Challenges
9.4 Infectious Vaccines Market Restraints
10 Global Market Forecast
10.1 Infectious Vaccines Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Infectious Vaccines by Type (2023-2030)
10.1.2 Global Forecasted Revenue of Infectious Vaccines by Type (2023-2030)
10.2 Infectious Vaccines Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Infectious Vaccines by Application (2023-2030)
10.2.2 Global Forecasted Revenue of Infectious Vaccines by Application (2023-2030)
10.3 Infectious Vaccines Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Infectious Vaccines by Region (2023-2030)
10.3.2 Global Forecasted Revenue of Infectious Vaccines by Region (2023-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
